Have a personal or library account? Click to login
Change of dosing paradigm in oncology Cover

Change of dosing paradigm in oncology

Forum of Clinical Oncology
Volume 14 (2023): Issue 2 (December 2023)
By: Sophia Papakatsika,  Myrsini Orfanidou,  Elpiniki Rentzeperi and  Christos Emmanouilides  
Open Access
|May 2024

Authors

Sophia Papakatsika

spapakatsika@gmail.com

Oncology Department, Interbalkan Medical Center, Pylaia, Central Macedonia, Greece

Myrsini Orfanidou

Oncology Department, Interbalkan Medical Center, Pylaia, Central Macedonia, Greece

Elpiniki Rentzeperi

Oncology Department, Interbalkan Medical Center, Pylaia, Central Macedonia, Greece

Christos Emmanouilides

Oncology Department, Interbalkan Medical Center, Pylaia, Central Macedonia, Greece
DOI: https://doi.org/10.2478/fco-2023-0022 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 3 - 6
Submitted on: Apr 27, 2023
|
Accepted on: Dec 22, 2023
|
Published on: May 20, 2024
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Chemotherapy dosing,
MTD,
novel therapies,
monoclonal antibodies,
sotorasib
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2024 Sophia Papakatsika, Myrsini Orfanidou, Elpiniki Rentzeperi, Christos Emmanouilides, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 14 (2023): Issue 2 (December 2023)Next article